-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 8, Roche announced that Gantenerumab, an anti-amyloid beta antibody administered subcutaneously, has been approved by the U.
From: Roche official website
This qualification is based on the SCarlet RoAD and Marguerite RoAD trials and other studies where Gantenerumab significantly reduced amyloid plaque deposits in the brain
Roche stated that Gantenerumab has the potential for home delivery as the first subcutaneous AD therapy currently under development to enter the late clinical stage
Roche stated that Gantenerumab has the potential for home delivery as the first subcutaneous AD therapy currently under development to enter the late clinical stage
AD is a progressive and fatal brain disease characterized by decreased memory, language, and other thinking abilities, as well as changes in mood and behavior
In June of this year, the FDA took the lead in accelerating the approval of Bojian’s Aducanumab based on biomarkers
In September, Eisai/Bojian submitted the BLA of its new Alzheimer's disease drug Lecanemab (BAN2401) to the FDA on a rolling basis, firing the first shot in the AD competition after Aducanumab